Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
76.94
-1.12 (-1.43%)
At close: May 22, 2026, 4:00 PM EDT
76.42
-0.52 (-0.67%)
After-hours: May 22, 2026, 7:38 PM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $19.36M in the quarter ending March 31, 2026, with 1,125.78% growth. This brings the company's revenue in the last twelve months to $105.82M, up 450.60% year-over-year. In the year 2025, Cytokinetics had annual revenue of $88.04M with 376.56% growth.
Revenue (ttm)
$105.82M
Revenue Growth
+450.60%
P/S Ratio
98.72
Revenue / Employee
$157,229
Employees
673
Market Cap
10.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.04M | 69.57M | 376.56% |
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
| Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
| Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
| Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
| Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
| Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
| Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
| Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
| Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
| Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
| Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
| Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
| Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
| Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
| Dec 31, 2005 | 8.91M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Halozyme Therapeutics | 1.51B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
CYTK News
- 23 hours ago - Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - MarketBeat
- 2 days ago - Cytokinetics to Hold Annual Meeting of Stockholders - GlobeNewsWire
- 4 days ago - Cytokinetics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Cytokinetics Slides: Corporate presentation - Filings
- 4 days ago - Cytokinetics initiated with a Buy, named a top pick at Citi - TheFly
- 4 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 9 days ago - Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) - GlobeNewsWire
- 10 days ago - Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire